Spinifex Pharmaceuticals appoints neuroscience expert as Chief Medical Officer

Ronald Marcus joins the Australian-US biotechnology company

Spinifex Pharmaceuticals, a pain drug development company, has appointed Dr Ronald Marcus as Chief Medical Officer. He will be responsible for driving the development of Spinifex’s leading drug candidate, EMA401, an oral treatment for chronic pain, and the company’s pre-clinical pipeline.

Marcus has more than 20 years’ pharmaceutical clinical development experience.

He joins biotechnology company Spinifex, which is located in Stamford, Connecticut, UN and Melbourne, Australia, after a successful career at Bristol-Myers Squibb (BMS), having held a number of senior leadership positions within BMS’s Neuroscience division.

Marcus has extensive experience in early and late drug development process and possesses both breadth and depth in all of the key functional areas of exploratory and late development, disease biology and regulatory affairs.

You may also like

Research & Development

Spinifex Pharmaceuticals sold to Novartis

Novartis will continue to develop the company’s programmes to address neuropathic pain
Regulatory

Neuropathic pain – EMA401

Pain that arises as a direct consequence of a lesion or disease affecting the somatosensory system is notoriously difficult to treat
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Subscribe now